Similar to other hematological malignancies, CD163+ TAMs are linked to poor prognosis in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), cutaneous T-cell lymphoma (CTCL) and splenic marginal zone lymphoma (SMZL) (140–144). This evidence concerns the gene CD163 and primary cutaneous T-cell non-Hodgkin lymphoma.